Investor Relations



We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in eight FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.




  • Jan 19

    Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021
  • Jan 12

    Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses


  • Regeneron Pharmaceuticals Q4 2020 Earnings Conference Call
    Feb 5
    8:30 AM EST
    Feb 5, 2021 | 8:30 AM EST